Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human GPR52 Stable Cell Line

    [CAT#: S01YF-0923-PY167]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    GPCR Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Based on this stable cell line, we also provide cell-based in vitro assays to evaluate the effects of your compounds or antibodies.

    Sub Cat Product Name Target Protein Species Host Cell Type Assay Types Inquiry Datasheet
    S01YF-1122-KX787 Magic™ Mouse GPR52 in Vitro cAMP Assay Mouse CHO-K1 cAMP Assay
    S01YF-1122-KX788 Magic™ Rat GPR52 in Vitro cAMP Assay Rat CHO-K1 cAMP Assay

    Product Information

    Target Protein
    GPR52
    Target Family
    Orphan Family
    Target Protein Species
    Human
    Host Cell Type
    HepG2;CHO-K1;HEK293
    Target Classification
    GPCR Cell Lines
    Gene ID
    Human: 9293
    UniProt ID
    Human: Q9Y2T5

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    GPR52, another G-protein-coupled receptor, has been identified as a potential therapeutic target in various conditions. Novel agonists for GPR52 have been discovered, which show promise in modulating G-protein signaling. Structural insights into GPR52 have revealed its ligand recognition mechanism, which could guide drug discovery efforts targeting this receptor. Furthermore, GPR52 has been associated with the regulation of cAMP levels in T cells, although its role in encephalitogenic responses remains to be elucidated.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human GPR52 Stable Cell Line (S01YF-0923-PY167). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Jennifer (Verified Customer)

    What is the role of GPR52 in dopamine signaling? May 26 2020

    chat Patrick Liam (Creative Biolabs Scientific Support)

    GPR52 is known to modulate dopamine signaling, and its activation can lead to increased dopamine release, making it a potential therapeutic target for conditions related to dopamine dysregulation, like Parkinson's disease and schizophrenia​ May 26 2020

    chat Sarah (Verified Customer)

    How is GPR52 involved in antipsychotic effects? Oct 17 2021

    chat Patrick Liam (Creative Biolabs Scientific Support)

    The activation of GPR52 has shown to have antipsychotic effects, possibly through the modulation of dopamine signaling. This has led to research into GPR52 as a potential target for antipsychotic drug development​​. Oct 17 2021

    Published Data

    Fig.1 The administration of c11 treatment led to a notable elevation in intracellular cAMP levels within the Cont-HepG2 group. However, this effect was noticeably subdued when applied to GPR52-KD HepG2 cells.

    The impact of the GPR52 agonist known as c11 on cAMP synthesis in HepG2 cells subjected to GPR52 siRNA or control siRNA treatment was investigated, involving a sample size of three. The cAMP levels were normalized based on protein concentration. The obtained data represents the mean values with standard error of the mean indicated. Statistical significance was denoted as # (p < 0.05) and ## (p < 0.01) for comparisons against c11-untreated control siRNA-treated cells, using an unpaired Student's t-test. Additionally, * (p < 0.05) and ** (p < 0.01) were used to indicate significance in comparisons between control siRNA-treated cells with c11 treatment and their counterparts, employing the same statistical test.

    Ref: Wada, Mitsuo, et al. "GPR52 accelerates fatty acid biosynthesis in a ligand-dependent manner in hepatocytes and in response to excessive fat intake in mice." Iscience 24.4 (2021).

    Pubmed: 33796846

    DOI: 10.1016/j.isci.2021.102260

    Research Highlights

    Power ME, et al. "The non-nutritive sweetener sucralose increases beta-arrestin signaling at the ." Canadian journal of physiology and pharmacology, 2023.
    In recent years, there has been a rise in the use of non-nutritive sweeteners in food products due to their low caloric content and strong sweetness compared to natural sugars. Despite evidence supporting their safety, there are studies contradicting this, suggesting that sweeteners may have negative effects on metabolism through unknown mechanisms. The authors propose that these sweeteners activate specific G protein-coupled receptors (GPCRs), particularly orphan receptors found in metabolically active tissues. Through a beta-arrestin-2 recruitment assay, the response of 64 orphan receptors to the sweeteners sucralose and saccharin was measured. It was found that GPR52 was the only receptor that significantly responded to the mixture of both sweeteners, with subsequent experiments revealing sucralose as the activating sweetener. This activation was concentration-dependent and did not further activate the receptor's CRE pathway, which is known to be constitutively active. This novel interaction between sucralose and GPR52 raises questions about the assumed lack of biological activity of sucralose, indicating the potential for off-target signaling through the activation of GPR52.
    Pubmed: 37748201   DOI: 10.1139/cjpp-2023-0199

    Wu Z, et al. "Dynamic Insights into the Self-Activation Pathway and Allosteric Regulation of ." Journal of chemical information and modeling, 2023.
    The subject of this abstract explored the mechanism of action for orphan G-protein-coupled receptor 52 (GPR52), which has been identified as a promising therapeutic target for central nervous system disorders. Through 6 mus Gaussian accelerated molecular dynamics (GaMD) simulations, the receptor demonstrated a self-activation pathway in which it transitions from an active state to a matching inactive crystal structure. The results also revealed the allosteric regulation between the extracellular orthosteric binding pocket and the intracellular G-protein-binding site, identifying key microswitch residues and the allosteric communication pathway. The role of ECL2 in this allosteric regulation was further supported by transfer entropy calculations. Overall, this work provides a detailed atomic-level understanding of the self-activation of GPR52, shedding light on a potential target for novel drug development.
    Pubmed: 37651308   DOI: 10.1021/acs.jcim.3c00672

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare